Carvedilol improves myocardial contractility compared with metoprolol in patients with chronic hibernating myocardium after revascularization

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 10, Issue 3, 2005, Pages 181-190

  Schwarz, Ernst R ^a,b   Gupta, Rajiv ^a   Diep, Tu Phuong ^b   Nowak, Bernd ^b   Kostin, Sawa ^c   Grohmann, Beate ^c   Uretsky, Barry F ^a   Schaper, Jutta ^c  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^c MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

Author keywords

Apoptosis; Carvedilol; Hibernating myocardium; Myocardial function

Indexed keywords

CARVEDILOL; FLUORODEOXYGLUCOSE F 18; METOPROLOL TARTRATE; TECHNETIUM 99M;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL DEGENERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART MUSCLE REVASCULARIZATION; HEART SCINTISCANNING; HEART VENTRICULOGRAPHY; HUMAN; HUMAN TISSUE; INTRAOPERATIVE PERIOD; MALE; MORPHOLOGY; MYOCARDIAL HIBERNATION; NEEDLE BIOPSY; NICK END LABELING; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; APOPTOSIS; CARBAZOLES; CHRONIC DISEASE; CORONARY ARTERY BYPASS; FEMALE; HUMANS; MALE; METOPROLOL; MIDDLE AGED; MYOCARDIAL CONTRACTION; MYOCARDIAL STUNNING; PROPANOLAMINES; VENTRICULAR FUNCTION, LEFT;

EID: 25444469925     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840501000306     Document Type: Article

References (35)

1. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 353:9-13, 1999
2. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353:2001-2007, 1999
3. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 334:1349-1355, 1996
4. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344:1651-1658, 2001
5. O'Keefe JH, Magalski AN, Stevens TL, et al. Predictors of improvement in left ventricular ejection fraction with carvedilol for congestive heart failure. J Nucl Card 7:3-7, 2000
6. Hall SA, Cigarroa CG, Marcoux L, et al. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with fladrenergic blockade. J Am Coll Cardiol 25:1154-1161, 1995
7. Olsen SL, Gilbert EM, Renlund DG, et al. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol 25:1225-1231, 1995
8. COMET Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): Randomised controlled trial. Lancet 362:7-13, 2003
9. Yue, TL, Cheng HY, Lysko PG, et al. Carvedilol, a new vasodilator and β adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 263:92-98, 1992
10. Schwarz ER, Kersting PH, Reffelman T, et al. Cardioprotection by carvedilol: Antiapoptosis is independent of β-adrenoreceptor blockage in the rat heart. J Cardiovasc Pharmacol Ther 8:207-215, 2003
11. CHRISTMAS Investigators. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): Randomized controlled trial. Lancet 362:14-21, 2003
12. Schwarz ER, Schaper J, vom Dahl JA, et al. Myocyte degeneration and cell death in hibernating human myocardium. J Am Coll Cardiol 27:1577-1585, 1996
13. Dodge HT, Sandler H, Baxley WA, Hawley RR. Usefulness and limitations of radiographic methods for determining left ventricular volumes. Am J Cardiol 18:10-24, 1966
14. Sheehan FH, Bolson EL, Dodge HT, et al. Advantages and applications of the centerline method for characterizing regional ventricular function. Circulation 74:293-305, 1986
15. Altehoefer C, vom Dahl J, Biedermann M, et al. Significance of defect severity in technetium-99m-MIBI SPECT at rest to assess myocardial viability: Comparison with fluorine-18-FDG PET. J Nucl Med 35:569-574, 1994
16. vom Dahl J, Altehoefer C, Sheehan FH, et al. Recovery of regional left ventricular dysfunction after coronary revascularization: Impact of myocardial viability assessed by nuclear imaging and vessel patency at follow-up angiography. J Am Coll Cardiol 28:948-958, 1996
17. Altehoefer C, vom Dahl J, Buell U, et al. Comparison of thallium-201 single-photon emission tomography after rest injection and fluorodeoxyglucose positron emission tomography for assessment of myocardial viability in patients with chronic coronary artery disease. Eur J Nucl Med 21:37-45, 1994
18. Weibel ER. Practical Methods for Biological Morphometry, Vol 1. New York: Academic Press; 1979
19. Schwarz ER, Schoendube FA, Kostin S, et al. Prolonged myocardial hibernation exacerbates cardiomyocyte degeneration and impairs recovery of function after revascularization. J Am Coll Cardiol 31:1018-1026, 1998
20. Rahimtoola S. The hibernating myocardium. Am Heart J 117:211-221, 1989
21. Braunwald E, Rutherford J. Reversible ischemic left ventricular dysfunction: Evidence for 'hibernating myocardium.' J Am Coll Cardiol 8:1467-1470, 1986
22. Elsaesser A, Muller KD, Skwara W, et al. Severe energy deprivation of human hibernating myocardium as possible common pathomechanism of contractile dysfunction, structural degeneration and cell death. J Am Coll Cardiol 39:1189-1198, 2002
23. Fallavollita JA, Malm BJ, Canty JM Jr. Hibernating myocardium retains metabolic and contractile reserve despite regional reductions in flow, function, and oxygen consumption at rest. Circ Res 92:48-55, 2003
24. Bax JJ, Visser FC, Poldermans D, et al. Time course of functional recovery of stunned and hibernating segments after surgical revascularization. Circulation 104:1314-1318, 2001
25. Nienaber CA, Bruncken RC, Sherman CT, et al. Metabolic and functional recovery of ischemic myocardial dysfunction after coronary angioplasty. J Am Coll Cardiol 18:966-978, 1991
26. Brundage BH, Massie BM, Bitvinick EH. Improved regional ventricular function after successful surgical revascularization. J Am Coll Cardiol 3:902-908, 1984
27. Metra M, Giubbini R, Nodari S, et al. Differential effects of β-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 102:546-551, 2000
28. Packer M, Antonopoulos GV, Berlin JA, et al. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: Results of a meta-analysis. Am Heart J 141:899-907, 2001
29. Reiken S, Gaburjakova M, Gaburjakova J, et al. Beta-adrenergic receptor blockers restore cardiac calcium release channel (ryanodine receptor) structure and function in heart failure. Circulation 104:2843-2848, 2001
30. Metra M, Nodari S, D'Aloia A, Bontempi L, Boldi E, Cas LD. A rationale for the use of beta-blockers as standard treatment for heart failure. Am Heart J 139:511-521, 2000
31. Beltrami CA, Finale N, Rocco M, et al. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation 89:151-163, 1994
32. Lim H, Fallavollita JA, Hard R, et al. Profound apoptosis-mediated regional myocyte loss and compensatory hypertrophy in pigs with hibernating myocardium. Circulation 100:2380-2386, 1999
33. Chen C, Ma L, Linfert DR, et al. Myocardial cell death and apoptosis in hibernating myocardium. J Am Coll Cardiol 30:1407-1412, 1997
34. Elsaesser A, Schlepper M, Klovekorn WP, et al. Hibernating myocardium: An incomplete adaptation to ischemia. Circulation 96:2920-2931, 1997
35. Elsaesser A, Vogt AM, Nef H, et al. Human hibernating myocardium is jeopardized by apoptotic and autophagic cell death. J Am Coll Cardiol 43:2191-2199, 2004